Related Experiment Videos
HER-2/neu expression in ovarian clear cell carcinomas
H Iwamoto1, H Fukasawa, T Honda
1Department of Obstetrics and Gynecology, Yamanashi Medical University, Tamaho, Nakakoma, Yamanashi, Japan.
Summary
HER2/neu overexpression is common in breast cancer but rare in ovarian clear cell carcinoma. This suggests Herceptin may have limited clinical value for treating this specific ovarian cancer subtype.
Area of Science:
- Oncology
- Molecular Biology
- Gynecologic Oncology
Background:
- HER2/neu, a receptor tyrosine kinase, is overexpressed in 25-30% of breast carcinomas, correlating with poor prognosis.
- Trastuzumab (Herceptin) is approved for HER2/neu-positive metastatic breast cancer, showing survival benefits.
- The role of HER2/neu in ovarian clear cell carcinoma (OCCC) remains largely uncharacterized.
Purpose of the Study:
- To investigate the expression status of HER2/neu in OCCC.
- To determine if HER2/neu overexpression in OCCC correlates with clinical prognosis.
- To establish a rationale for the potential clinical use of Herceptin in OCCC.
Main Methods:
- Immunohistochemical staining for HER2/neu was performed on 15 OCCC tissue samples.
- HercepTest (DAKO) was utilized for standardized HER2/neu detection.
- Expression levels were analyzed to identify overexpression patterns.
Main Results:
- HER2/neu overexpression was detected in only one out of 15 OCCC cases (approximately 6.7%).
- This incidence is significantly lower compared to HER2/neu overexpression rates in breast carcinoma.
- The findings indicate HER2/neu overexpression is uncommon in OCCC.
Conclusions:
- HER2/neu overexpression is infrequent in ovarian clear cell carcinomas.
- Consequently, Trastuzumab (Herceptin) may offer limited clinical benefit for the majority of OCCC patients.
- Further research is needed to explore alternative therapeutic targets for OCCC.